Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis.

Daniel M.F. Claassens,Thomas O. Bergmeijer,Gerrit J.A. Vos,Renicus S. Hermanides,Arnoud W.J. van t Hof,Pim van der Harst,Emanuele Barbato,Carmine Morisco,Richard M. Tjon Joe Gin,Folkert W. Asselbergs,Arend Mosterd,Jean-Paul R. Herrman,Willem Dewilde,Paul W.A. Janssen,Johannes C. Kelder,Bakhtawar K. Mahmoodi,Vera H.M. Deneer,Jurriën M. ten Berg

Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis.

2021

Daniel M.F. Claassens
Thomas O. Bergmeijer
Gerrit J.A. Vos
Renicus S. Hermanides
Arnoud W.J. van t Hof
Pim van der Harst
Emanuele Barbato
Carmine Morisco
Richard M. Tjon Joe Gin
Folkert W. Asselbergs
Arend Mosterd
Jean-Paul R. Herrman
Willem Dewilde
Paul W.A. Janssen
Johannes C. Kelder
Bakhtawar K. Mahmoodi
Vera H.M. Deneer
Jurriën M. ten Berg

Background: Guidelines favor ticagrelor or prasugrel over clopidogrel in patients with myocardial infarction. However, the POPular Genetics trial (Patient Outcome After Primary Percutaneous Coronar...

Keywords:

Medicine
Clopidogrel
Ticagrelor
Percutaneous
Genetics
Pharmacogenetics
Myocardial infarction
Prasugrel
Percutaneous coronary intervention
Acute coronary syndrome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations